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Abstract
Background: To evaluate the interchangeability of perfusion parameters obtained with help of models used for
post-processing of perfusion-CT images in pancreatic adenocarcinoma and to determine the mean values and
ranges of perfusion in different tumour gradings.
Methods: Perfusion-CT imaging was performed prospectively in 48 consecutive patients with pancreatic
adenocarcinoma. In 42 patients biopsy-proven tumor grading was available (4 × G1/24 × G2/14 × G3/6× unknown).
Images were post-processed using a model based on the maximum-slope (MS) approach (blood flow-BFMS) + Patlak
analysis (P) (blood volume [BVP] and permeability [k-transP]), as well as a model with deconvolution-based (D) analysis
(BFD, BVD and k-transD). 50 mL contrast agent were applied with a delay time of 7 s. Perfusion parameters were
compared using intraclass correlation coefficient (ICC), the Wilcoxon matched-pairs test and Bland-Altman plots.
Results: Forty eight VOIs of tumours were outlined and analysed. Moderate to good ICC values were found for the
perfusion parameters (ICC = 0.62–0.75). Wilcoxon matched-pairs revealed significantly lower values (P < .001 and 0.008),
for the BF and BV values obtained using the maximum-slope approach + Patlak analysis compared to deconvolution
based analysis. For k-trans measurement, deconvolution revealed significantly lower values (P < 0.001). Different
histologic subgroups (G1-G3) did not show significantly different functional parameters.
Conclusion: There were significant differences in the perfusion parameters obtained using the different calculation
methods, and therefore these parameters are not directly interchangeable. However, the magnitude of pairs of
parametric values is in constant relation to each other enabling the use of any of these methods. VPCT parameters did
not allow for histologic classification.
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Background
Pancreatic cancer is one of the leading malignancies of the
digestive tract [1]. It also has the poorest prognosis of all
gastro-intestinal cancers. Over the last decades, there has
been a continuous increase in diagnosed patients in
Western industrialized nations. Only 2% of annually
diagnosed patients outlive the following 5 years [2]. The
most common pancreatic cancer is the adenocarcinoma of
the pancreatic head [1]. Tumour characterization and
accurate delineation is essential for staging and pre-
operative planning, as in addition to TNM staging, the
degree of malignancy, called tumour grading is a decisive
parameter of survival [3, 4]. So far, tumour grading is done
histologically, which requires invasive biopsy sampling.
Hence the development of a non-invasive method of
tumour grading would be highly desirable.
Volume perfusion CT (VPCT) is a relatively new
modality that has been increasingly used for oncologic
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imaging over the last years [5]. Based on repetitive
scanning of a tissue volume after contrast injection,
VPCT enables the measurement of functional parameters
of tumour vascularity like blood flow (BF), blood volume
(BV) and the permeability of capillaries (permeability sur-
face area product, or k-trans).
Recent studies show the capability of perfusion CT to
evaluate tumour vascularization and monitor chemotherapy,
radiation therapy or even effect of novel functional
drugs affecting tumour environment and angiogenesis
[6–10]. One preliminary study suggested that even a
non-invasive tumour grading with VPCT might be possible
in the case of pancreatic adenocarcinoma [6].
There are different calculation methods for the post-
processing of perfusion-CT images: the compartment
analysis assuming one (maximum slope) or two compart-
ments (Patlak) and the deconvolution analysis. In other
tumour tissues, several studies have already demonstrated
significant differences in the calculated perfusion values
between the different mathematical models [11–13].
For this purpose, reliability of CT-perfusion data is
imperative. Besides an optimized CT-examinational
protocol, standardization of perfusion quantification
methods (post-processing) is essential, as well as know-
ledge about comparability of results using these different
mathematical methods for perfusion calculation.
However, for reproducibility of studies and for deter-
mining cut-off values it is important to know if the dif-
ferent models deliver comparable results. For this reason
this study explored for pancreas adenocarcinoma to
which extent both models (maximum slope + Patlak and
deconvolution) are comparable and if these functional
parameters allow for a reliable tumour grading.
Methods
Clinical data
Inclusion criteria for the VPCT study were: Patients with
suspicion of pancreatic cancer before treatment who
agreed to take part in this study after informed consent.
Exclusion criteria for VPCT were: Poor kidney function
(GFR < 45 ml/min), pregnancy, allergy to contrast agent
or iodine and incompliant patient unable to hold their
breath.
Between September 2011 and November 2014, a total
of 48 patients (28 male, 20 female; mean age: 69 ±
9 years, range: 39–84, respectively) were eligible for
VPCT data analysis and prospectively enrolled in the
study. In 42 of these patients, histologic data was available.
In 4 cases patients refused a biopsy. In two cases, the
biopsy did not contain sufficient diagnostic specimen for
the pathologist. However, in time diagnosis of pancreatic
cancer could be clearly made due to the presence of
tumour markers and available imaging.
VPCT of the entire pancreas was performed. All biopsy
specimens were examined by a pathologist and graded
according to the AJCC Classification [14] and as described
by Hruban et al.[15].
CT Perfusion scanning technique
All examinations were performed on a 128-row CT
scanner (Somatom Definition AS+, Siemens Healthcare,
Forchheim, Germany). The CT protocol consisted of a
non-enhanced abdominal low-dose CT (NECT) (40 mAs,
100 kV, 5.0 mm slice thickness, collimation 128*0.6 mm,
tube rotation time 0.5 s, pitch 0.6), which was obtained to
localize the pancreas. Subsequently, a VPCT of the
tumour using adaptive spiral scanning technique was per-
formed. In the adaptive spiral mode the z-range is scanned
continuously with a shuttle movement of the patient table.
Perfusion parameters were: 80 kV, 100/120mAs (for
patients </> 70 kg, respectively), collimation 64 × 0.6 mm
with z-flying focal spot (Z coverage 6.9 cm) and 26 CT-
whole coverages of the pancreas within a total scan time
of 40s. Patients were asked to resume shallow breathing
for the entire duration of the study. 50 ml Ultravist 370
(Bayer Vital Leverkusen, Germany) were injected at a flow
rate of 5 mL/s in an antecubital vein followed by a saline
flush of 50 ml NaCl at 5 mL/s, and a fixed start delay of
7 s. Contrast medium was administered by using a dual-
head pump injector (Stellant, Medtron, Saarbruecken,
Germany). One set of axial images with a slice thickness
of 3 mm for perfusion analysis was reconstructed without
overlap, using a smooth tissue convolution kernel (B10f).
All images were transferred to an external workstation
(Multi-Modality Workplace, Siemens) for analysis. The
mean effective whole-body dose values for VPCT exami-
nations of the pancreas are estimated 7.0 mSv for men
and 7.1 for women [16].
CT Perfusion analysis
All data sets were transferred to a dedicated workstation
(Syngo MMWP, VE 36A, Siemens Healthcare, Forchheim,
Germany) and quantitative data evaluation was performed
with a commercial software (Syngo Volume Perfusion CT
Body). Automated motion correction and noise reduction
of all datasets were applied by using an integrated motion
correction algorithm with non-rigid deformable registra-
tion for anatomic alignment. A circular region of interest
(ROI) was placed in the abdominal aorta, which provided
the arterial input function for the computations. A second
volume of interest (VOI) was placed in the pancreatic
carcinoma for calculating the tumour perfusion. The
VOI were chosen as large as possible and placed to avoid
vessels and artefacts in a slice by slice approach (Fig. 1).
For perfusion calculation we used two mathematical
calculation methods (models): Compartmental analytic
models (maximum slope (BFMS) + Patlak analysis
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(BVP, k-transP) vs. deconvolution model (BFD, BVD
and k-transD). These two different kinetic calculation
software programs used are both FDA approved and are
part of the post-processing software recommended by the
vendor. Perfusion parameters (BF, BV and k-trans) of both
models were compared.
Statistical analysis
Statistical calculation was performed using JMP 11 (SAS
Institute, Cary NC, USA) and SPSS 23 (Chicago, IL, USA).
Mean values of BF, BV and k-trans as well as of their
standard deviations (SD) are reported. Differences
between the functional parameters were compared using
the Wilcoxon matched-pairs test and Bland-Altman plots.
Second, the mean difference, SD of the differences and the
95% limits of agreement (mean difference − 2 × SD and
mean difference + 2 × SD) were calculated for each of the
perfusion parameters. If Bland-Altman plots showed a
linear relation a linear regression analysis was performed.
Statistical significance was established at a P value <0.05.
Agreement between the different perfusion measures
was assessed using the intra-class correlation coefficient
(ICC) as discussed by Shrout and Fleiss [17]. A value
close to 1 indicates excellent agreement between the two
readings. Additionally the Pearson’s linear correlation
coefficient was calculated for the corresponding func-
tional parameter values obtained with the different
methods. Parameters for different histological grading
were compared using an ANOVA analysis.
Results and discussion
Forty eight Patients (28 men, 20 women, mean age: 69,
range: 49–85 years) with untreated pancreatic adeno-
carcinoma were outlined and analysed. In total 28/48
tumours were localized in the head, 10/48 in the corpus
and 10/48 in the pancreatic tail. In 42 patients biopsy-
proven pathologic tumour grading was available (4 G1,
24 G2, 14 G3). The mean tumour size (measured the
largest diameter) was 4.0 cm (range: 1.7–8.1 cm).
The calculated values of the blood flow (mL/100 g
tissue/’) in the compartment analysis (maximum slope,
BFMS) were significantly lower than the calculated
values in the deconvolution (BFD) method, with values
of 20.4 ± 9.7 ml/min/100 g (range: 1.6–48.22 ml/min/100 g)
Fig. 1 Example of a VPCT study a 62 year old patient with an adenocarcinoma in the pancreatic head. a–f) Colour maps of functional parameters:
a Blood flow according to Max. slope Mode (BFMS; 26 ml/min/100 g), b BF calculated with Deconvolution method (BFD 42 ml/min/100 g). c Blood
volume calculated with Patlak Model (BVP 6 ml/100 g), d Blood volume calculated with Deconvolution method (BVD 9 ml/100 g), e K-trans calculated
with Patlak Model (k-transP 16 ml/min/100 g), f K-trans calculated with Deconvolution method (9 ml/min/100 g)
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in the maximum slope respectively 36.9 ± 16.0 ml/min/100 g
(range: 5.54–68.61 ml/min/100 g) in the deconvolution
method (p < 0.004) (Table 1).
The calculations of blood volume (BVMS vs. BVD)
(mL/100 g tissue) showed similar results, with significantly
higher values in the deconvolution method (p = 0.004).
We calculated a mean blood volume value of 5.6 ±
5.5 ml/100 g (range: 0.81–25.71 ml/100 g) with the
compartment analysis (Patlak analysis), whereas the decon-
volution method yielded a mean value of 7.3 ± 4.7 ml/100 g
(range: 1.56–21.58 ml/100 g). This difference was also
significant (p < 0.001).
The calculated vessel wall permeability (k-transP vs.
k-transD, mL/100 g tissue) showed a different trend.
This parameter yielded higher values for the compartment
analysis (Patlak analysis) than for the deconvolution
method, with values of 18.9 ± 9.8 (range: 4.86–41.77),
respectively 12.4 ± 8.2 (range: 0.5–30.34) (p < 0.001).
The Bland-Altman plots of the perfusion parameters
showed no systematic errors for higher or lower mean
values in BV and k-trans (Fig. 2). For BF, Bland-Altman
Plots showed a linear relation with higher differences at
high absolute values. Subsequent linear regression
analysis showed a good linear fit with a resulting slope
of 1.5. (Fig. 3a).
Despite significant differences in the calculated perfu-
sion parameters between the different models, moderate
to good correlation between the functional perfusion-
based parameters with regard to ICC and Pearson’s linear
correlation coefficient (Table 2 and Fig. 3) were found.
Among the three histological differentiation subgroups
(G1-G3), functional parameters did not vary signifi-
cantly. No functional fingerprints could be established
for less differentiated lesions. This was consistent between
the mathematical models (Table 3).
CT perfusion imaging is evolving rapidly. Based on a
recently published review recommending how to
optimize CT-perfusion protocols in the light of current
knowledge about strengths and limitations of the available
mathematical calculation models and suggesting ways to
standardize the state of the art examinational protocols,
the aim of the study was to make a comparison of results
obtained with the recommended perfusion protocol and
available calculation methods and report about the
magnitude of obtained perfusion values as well as of
their ranges and correlations with the histologic differ-
entiation grade [18].
Our results clearly show that quantification of pancreatic
carcinoma perfusion is feasible with the proposed VPCT-
examinational protocol and that the measured perfusion
values are in line with those reported in previous works
dealing with this issue and using comparable perfusion
protocols [19]. Moreover, they confirm the knowledge that
results of the two used mathematical calculation methods
significantly differ from each other and are thus not dir-
ectly interchangeable, but that the magnitude of their pairs
of calculated parametric values stays in constant relation to
each other for BV and k-trans values. BF values show a lin-
ear relationship with higher values for the deconvolution
method and a linear relationship with a slope of 1.5. These
differences are systematic differences explainable by the
different underlying mathematical models. The Maximum
slope model underestimates BF because venous outflow is
not considered by the model. This error is proportional to
the absolute BF. Accordingly the relation between BFMS
and BFD is a constant ratio. The presented cohort
comprising 48 cases is currently the largest VPCT series of
pancreatic adenocarcinoma. There is a growing amount of
data from the literature reporting perfusion values of the
pancreas. However this data is very heterogeneous with
regard to technical parameters and included subjects.
Accordingly literature values are hard to compare. In line
with previous reports, in our study, blood flow values were
found to be significantly lower when calculated with the
compartment model compared to values obtained with the
deconvolution method. The same trend was observed also
for the measured absolute values of blood volume which
proved to be significantly lower when calculated with the
compartment model vs. the deconvolution method. Ex-
pectedly, the calculated k-trans values were lower for the
deconvolution method vs. the two-compartment model
(Patlak model). Xu et al. reported blood flow and blood
volume values in the tumour tissue of 29.5 ml/min/100 g
and 59.72 ml/100 g, respectively, both measured with the
deconvolution method [20]. The blood flow value was thus
lower in their study, but still in the same range with our
deconvolution measured values. However, the blood
volume was noticeably higher than in our study (59.7 ml/
100 g vs. 7.3 ml/100 g). Similar results were reported also
by Klauß et al. who reported BF values for pancreatic
Table 1 Functional VPCT values for adenocarcinomas
Parameter Max. slope Patlak Deconvolution Mean Difference 95% limits of agreement p-valuea
BF (ml/min/100 g) 20.4 ± 9.7 36.9 ± 16.0 16.5 ± 8.9 −0.9;33,9 <0.001
BV (ml/100 g) 5.6 ± 5.5 7.3 ± 4.7 −1.7 ± 4.6 −10.7;7.3 0.004
k-trans (ml/min/100 g) 18.9 ± 9.8 12.4 ± 8.2 6.5 ± 5.8 −4.9;17.9 <0.001
Mean values of functional perfusion parameters for n = 48 adenocarcinomas obtained with Maximum slope-, Patlak- and deconvolution models
afor Wilcoxon matched-pairs test
Abbreviations: BF blood flow, BV blood volume, G1-3 tumor grading
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adenocarcinoma calculated with the Patlak analysis that
were in the same range with ours; however, calculated BV
values proved again significantly higher than in our popu-
lation (38.9 ml/100 g vs. 5.6 ml/100 g) [21]. These discrep-
ancies highlight the imperative of using robust
examinational protocols as well as kinetic calculation
models. According to our experience, a blood volume
significantly higher than the corresponding blood flow is
difficult to explain, in particular in a tumour with known
desmoplastic stroma and lowered vascularisation. Notably,
the data of Klauß et al. was obtained using a dual-energy
perfusion protocol. On the contrary, Tan et al. obtained
considerably higher BF values 60 ± 15.3 ml/min/100 g
using lower temporal resolution during the first pass
phase [22]. In particular, in the maximum slope model,
temporal resolution between the start of contrast agent
administration and the peak enhancement should be kept
as high as technical feasible in order to avoid false high
miscalculation [18]. Accordingly, the report by Li et al.
using a reduced-dose examinational CT-perfusion proto-
col comparable to ours yielded similar results for BF,
BV as well as for k-trans using the Patlak calculation
Fig. 2 Bland-Altman plots of Blood flow (a, BF), Blood volume (b, BV) and Permeability (c, k-trans). a The plot confirms higher values for BFD
compared to BFMS with higher differences for higher absolute values. b Lower absolute values for BVP compared with BVD. There are no systematic
deviations in high or low absolute values. c K-transD shows lower values than k-transP without systematic deviations throughout the range of the
values. Abbreviations: BFD = blood flow calculated with deconvolution; BFMS = blood flow calculated with maximum slope; BVD = blood
volume calculated with deconvolution; BVP = blood volume calculated with Patlak; k-trans = permeability surface area product, or k-trans;
k-trans; D = k-trans calculated with deconvolution; k-trans P = k-trans calculated with Patlak
Table 2 Correlation between VPCT parameters obtained with
different calculation models
Parameter ICC Pearsons r
Blood Flow (BF) (ml/min/100 g) 0.62 0.89
Blood Volume (BV) (ml/100 g) 0.62 0.60
Permeabilty (k-trans) (ml/min/100 g) 0.75 0.80
ICC and Pearson’s linear correlation coefficient of the functional parameters
obtained with Maximum slope-, Patlak- and deconvolution models
Abbreviations: BF blood flow, BV blood volume, G1-3 tumor grading
Schneeweiß et al. Cancer Imaging  (2016) 16:43 Page 5 of 8
model [23]. Another essential aspect with perfusion-
CT is that concerning the total examination time.
This is in particular essential for the calculation of
k-trans. Spira et al. demonstrated significant decrease of
BV values and concomitantly significant increase of
k-trans-values with progressively shortened measure-
ment time (down to 39 s) in lung carcinomas [24]. Accord-
ingly it can be assumed that difference between k-transD
and k-transP is caused partly by the limited scan time.
The use of perfusion-CT in other tumour tissues as
reported by several previous studies has already demon-
strated significant differences between the different
mathematical models [11–13, 25]. A study from Djuric-
Stojanovic et al., examining the perfusion parameters of
oesophageal carcinoma, yielded a similar tendency with
blood flow values showing significantly higher values for
the compartmental analysis [13]. Similar to our study on
pancreatic lesions, a good correlation for the blood
Fig. 3 Plotted data of thee corresponding functional parameters calculated with both methods. Red line is the linear regression function for each
functional parameter with indicated ICC and Pearsons r. a Linear regression analysis for BFMS vs. BFD showed a strong correlation and a good
linear fit with a resulting slope of 1.5. (b and c) Despite significant differences between Patlak- and deconvolution models (BVP vs. BVD and k-transP vs.
k-transP), moderate to good correlation between the functional perfusion-based parameters with regard to ICC and Pearson’s linear correlation
coefficient were found. Abbreviations: BFD = blood flow calculated with deconvolution; BFMS = blood flow calculated with maximum slope;
BVD = blood volume calculated with deconvolution; BVP = blood volume calculated with Patlak; k-trans = permeability surface area product,
or k-trans; k-trans; D = k-trans calculated with deconvolution; k-transP = k-trans calculated with Patlak
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volume between the compartment- and the deconvolution
model has also been shown for malignancy in the lung
(0.86), spleen (0.9) and brain (0.79) [26].
It has been suggested that perfusion-based tumour
characterisation could be a non-invasive tumour grading
method in pancreatic adenocarcinoma [6, 27]. This is a
highly interesting topic as tumour grading is a very
important prognostic factor in patients suffering from
pancreatic carcinoma [3]. However despite using a simi-
lar protocol, in the present study none of the applied
models based on perfusion parameters proved able to
reliably discriminate between degrees of tumour differen-
tiation. However, even in this respect, the studies are not
directly comparable as the applied parameters Peak
Enhancement Intensity (PEI) which indicates the peak
attenuation reached by the tissue after contrast media
injection and BV vs. BF, BV and k-trans and the histo-
logic subdivisions were different. We believe that in the
above mentioned study, the temporal resolution (every 5 s)
may have been too low in order to accurately determine
the PEI and BF [6]. However, we agree that grading does
not seem to be possible if based solely on the parameter
BF. The reason for the inconclusiveness of the present data
remains unclear. However there are also some concerns
with regard to histologic analysis which might have led to
these results. At first the histologic specimen is usually very
small and limited to a small part of the tumor. It is known
that the pancreatic adenocarcinoma consists of several
parts of varying dedifferentiation [15]. Accordingly, the
histologic specimen might not be representative for the
whole tumour. Second, the perfusion values in pancreatic
adenocarcinoma are generally very low, sometimes only
slightly above noise level. By this, the measurement of rela-
tive differences within this group is intrinsically difficult as
differences are expected to be very small.
Conclusions
In summary, both perfusion calculation methods seem to
be applicable, but cannot be directly compared. Never-
theless, the magnitude of pairs of parametric values is
in constant relation to each other enabling the use of
any of these methods for clinical trials.
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